Topics

JPM20: Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective

04:15 EST 15 Jan 2020 | BioPharmaDive

Roche, maker of the last decade's top cancer drugs, is betting that neuroscience research can make strides in the 2020s — an outlook that contrasts with research retreats by the pharma's peers. 

Original Article: JPM20: Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective

NEXT ARTICLE

More From BioPortfolio on "JPM20: Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...